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Abstract
Background: We compared six kinetic models with and without the requirement of arterial cannulation for
estimating the binding potential of [N-methyl-
11C]mirtazapine in the living human brain.
Methods: Distribution volumes of [N-methyl-
11C]mirtazapine in brain regions were estimated using single- and
two-tissue compartment models as well as a graphical plasma input model. The two-tissue compartment model
provided a direct estimate of the binding potentials of [N-methyl-
11C]mirtazapine in brain regions, while binding
potentials of the single-tissue compartment model and the graphical plasma input model were estimated
indirectly from ratios of distribution volumes in brain regions. We obtained also direct estimates of binding
potentials using a graphical reference tissue model and two nonlinear reference tissue models.
Results: The two-tissue compartment model required several fits with different initial guesses for avoiding negative
values of parameters. Despite the extra fits, estimates of distribution volumes and binding potentials of [N-methyl-
11C]mirtazapine obtained by the two-tissue compartment model were far more variable than those produced by
the other methods. The graphical plasma input method and the graphical reference tissue method provided
estimates of the binding potential that correlated closely, but differed in magnitude. The single-tissue
compartment model provided relatively low estimates of binding potentials with curves that failed to fit the data
as well as the three other methods that used the entire series of positron emission tomography data. The
reference tissue method and the simplified reference tissue method provided similar, consistent estimates of
binding potentials. However, certain assumptions of the simplified reference tissue method may not be fulfilled by
the radioligand.
Conclusion: The reference tissue method is appropriate for estimating the binding potential of [N-methyl-
11C]
mirtazapine in regions of the human brain so that the binding potential of [N-methyl-
11C]mirtazapine can be
estimated without arterial cannulation.
Keywords: [
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Background
Mirtazapine is an atypical antidepressant drug belonging
to a class of compounds known as noradrenergic and
specific serotonergic antidepressants [1-5]. Extensive
clinical trials have shown mirtazapine to be among the
most effective antidepressants [3,4]. The antidepressant
enters the central nervous system rapidly [6], which
makes it a suitable candidate for short-term kinetic
modeling [7]. Previously, we radiolabeled mirtazapine
with
11C (Figure 1) and studied it by positron emission
tomography [PET] in anesthetized pigs [8,9]. We
obtained arterial blood samples for kinetic data analysis
and found that the compound had a differential distri-
bution in brain regions, with the highest binding poten-
tials in the frontal and temporal cortices, intermediate
binding potential in the thalamus, and low binding
potentials in the striatum, hypothalamus, and brainstem.
Thereafter, we initiated PET studies with arterial sam-
pling in humans and used a single-tissue compartment
model to estimate brain regional binding potentials [10].
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markedly in the distribution and binding of [N-methyl-
11C]mirtazapine, which has furthered our interest in
using the radioligand for PET. Experience with arterial
cannulation in humans has, however, indicated that the
procedure can be disadvantageous for routine brain ima-
ging [7], in part occasionally due to discomfort at the
cannulation site. Here, we carried out the present study
to determine whether a reference region method, which
requires no arterial blood sampling, can also provide
reliable estimates of binding potentials of [N-methyl-
11C]mirtazapine in human brain regions.
Methods
Subjects
The study was approved by the Danish Medicines
Agency, the Ethics Committee of Aarhus Municipality,
and the Committee for Good Clinical Practice of Aarhus
University Hospital. We used five males (ranges 37 to 66
years old, 70 to 94 kg) who gave informed consent to
participate in the study after receiving a written and oral
account of the project. They were currently in good
general health with no indication of past or present
mental illness.
Scanning procedure
For brain imaging, we used an ECAT EXACT HR PET
camera (CTI/Siemens, Knoxville, TN, USA) with a
radiation shield located on each side of the neck (Neu-
roShield
®, Scanwell Systems, Montreal, Canada). After a
transmission scan, subjects received an intravenous
injection of [N-methyl-
11C]mirtazapine (ranges: radioac-
tivity injected = 175 to 413 MBq, specific activities = 13
to 67 GBq/μmol, stable mirtazapine dosage = 15 to 50
μg) at the start of a 60-min dynamic PET scan of 28
f r a m e s( 6×1 0s ,4×3 0s ,7×6 0s ,5×1 2 0s ,4×3 0 0
s, 2 × 600 s) recorded in 3D mode. PET data were
reconstructed using filtered backprojection and a Han-
ning filter with a cutoff frequency of 0.5 per cycles,
resulting in a special resolution (FWHM) of about 5
mm. Correction for attenuation was based on a trans-
mission scan. The dynamic PET data were decay-cor-
rected to the scan start.
Radiochemistry, blood chemistry, and metabolite analysis
[N-methyl-
11C]Mirtazapine was prepared from (±)-N-
desmethyl mirtazapine (Z)-2-butenedioate, and analytical
high-performance liquid chromatography [HPLC], deter-
mination of radiochemical purity, and product identity
were done as described elsewhere [9,11]. Thirty-five
b l o o ds a m p l e s( 1 8×1 0s ,4×3 0s ,5×1m i n ,7×5
min, 1 × 15 min) were obtained manually from an ante-
cubital artery and were decay-corrected to the scan
start. The fraction of unchanged [N-methyl-
11C]mirtaza-
pine in the plasma was determined with radiodetection
by integration of the peak corresponding to the radio-
pharmaceutical identity and was expressed as a percen-
tage of the total of all radioanalytes recovered by HPLC.
Seven radiochemical fractionations of extracts of plasma
samples were measured at 1, 2.5, 5, 15, 25, 40, and 60
min. A double-exponential function was fitted to these
measurements and was used to estimate the continuous
time-course of the radiochemical fractions of [N-methyl-
11C]mirtazapine needed to calculate the metabolite-cor-
rected arterial input function.
Image analysis
T h ed a t ao ft h ed y n a m i c[ N-methyl-
11C]mirtazapine
scan were summed for each subject, and each summed
image was coregistered automatically using a software
based on the medical image NetCDF [MINC] program-
ming package developed at the Montreal Neurological
Institute [MNI]. Briefly, the summed PET scans were
converted into the MINC format and were linearly
registered to the MNI/International Consortium for
Brain Mapping [ICBM] 152 T1 brain template [12].
The transforms were concatenated to produce the
transformation used for bringing the dynamic PET
images into the MNI/ICBM 152 common standardized
space.
Representative regions of interest were obtained auto-
matically from each subject’s data by a custom-made
software and a segmented atlas of the human brain [13].
Time-activity curves [TACs] were generated from the
dynamic PET study for five regions: the cerebellum
N
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Figure 1 Structure of [N-methyl-
11C]mirtazapine.
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frontal lobe (region 4), and thalamus (region 5).
Kinetic analyses
Time-activity curves for each subject were analyzed
using six kinetic methods: (A) single-tissue compart-
ment model with uncorrected and metabolite-corrected
arterial plasma input functions, (B) two-tissue compart-
ment model with uncorrected and metabolite-corrected
arterial plasma input functions, (C) graphical plasma
input model with metabolite-corrected arterial plasma
input function [14], (D) graphical reference tissue model
with a cerebellum TAC [15], (E) reference tissue model
with a cerebellum TAC [16], and (F) simplified reference
tissue model with a cerebellum TAC [17]. Methods A
and B use metabolite-corrected arterial plasma curves as
input function to the kinetic model, and uncorrected
arterial plasma curve including metabolites for the
blood volume. The reference tissue models, namely
methods D, E, and F, use a cerebellum TAC instead of
plasma input functions and do not require blood sam-
pling. Method D can be applied with or without a k2
correction [15]; we excluded the correction to maintain
a linear method without assumptions about the k2
values.
All models can be described in terms of micropara-
meters: K1 (ml ml
-1 min
-1) denotes the influx rate con-
stant of the parent compound from the plasma to the
free tissue compartment; k2 (min
-1)i st h er a t ec o n s t a n t
of transfer from the free to the plasma compartment; k3
(min
-1) is the rate constant for transfer from the free to
the bound compartment; k4 (min
-1) is the rate constant
for transfer from the bound to the free compartment;
and V0 (ml ml
-1) is the fractional blood volume in the
brain. In methods A and B, we assumed a fixed frac-
tional blood volume of 7% [18]. Estimates of micropara-
meters may be uncertain due to noise. However, data
analyses of receptor studies focus on physiologic macro-
parameters, such as distribution volumes [VT] (the ratio
at equilibrium of the tracer concentration in the tissue
to that in the plasma) and binding potentials [BPND]
(the ratio at equilibrium of a specifically bound tracer to
that of a non-displaceable tracer in the tissue), which
are more stable and can be derived in terms of the
microparameters. Method A provides estimates of the
distribution volumes (VT = K1/k2). In addition, indirect
estimates of binding potentials were calculated for the
binding regions by relating fitted values for the distribu-
tion volume in the binding region to that of the refer-
ence region, assuming that distribution volume of the
non-displaceable compartment [VND] in the receptor-
deficient reference region and in the receptor-rich bind-
ing region are equal:
BPND = (VT − VND)/VND. (1)
Method B provides estimates of the distribution
volumes (VT =( K1/k2)( 1+k3/k4)) and binding poten-
tials (BPND = k3/k4). Method C provides estimates of VT
as the slope of a linear regression to the late linear part
of the Logan representation. For method C, BPND can
be indirectly calculated according to Equation 1. Method
D provides estimates of the distribution volume ratio
VT/VND as the slope of a linear regression from which
the binding potential (BPND = VT/VND -1 )i sd e r i v e d
(Equation 1). Methods E and F directly include BPND =
k3/k4 as a model parameter.
It has been shown for neuroreceptor modeling that
weights should not be based on noisy TACs and that uni-
form weighting is recommended if nothing is known
about the noise of the measurements [19]. We tested two
simple weighting schemes by comparing kinetic para-
meters estimated by nonlinear regression with uniform
weighting and with weighting by frame duration. Good-
ness-of-fit was measured by the Akaike criterion [20].
Parameter estimates may fluctuate considerably when
fitted by the nonlinear methods A, B, E, and F. We report
the best fits and their corresponding parameter estimates
that represent the best mathematical representation of
the data as found by an automatic optimization routine
[21]. For noisy data, the resulting parameters can depend
on the initial guess due to local minima, which may be
unphysiologic and even inclu d en e g a t i v em i c r o p a r a -
meters that are not compatible with the kinetic model. In
these cases, the data analysis is less straightforward since
quality control of the fits is needed. In this study, our
only exclusion criterion was the negative parameters, and
those fits were remade with a different initial guess.
Otherwise, we report parameters from the fits that
yielded the lowest Akaike value. Except for the non-nega-
tivity constraint, we did not introduce subjective upper or
lower limits for parameter estimates. In reality, we only
had problems with local minima when using Method B
that led to estimates of k3 and k4 that were particularly
unreliable; its sensitivity to noise was systematically dealt
with by making 20 fits using randomized initial guesses
and reporting the parameters from the fit with the lowest
Akaike value with non-negative parameters. For the
other methods, we would get the same physiologically
reasonable parameter estimates using any reasonable
initial guess. Thus, the extensive procedure using 20 fits
was not necessary for the other methods.
We used nonparametric tests (chi-square test, Krus-
kal-Wallis H test, Mann-Whitney U test, and Spear-
man’s rho) with Bonferroni correction for multiple
comparisons for determining the statistical significance
of the results.
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Figure 2 shows time-radioactivity curves for [N-methyl-
11C]mirtazapine in the bloodstream and the brain. Con-
siderable amounts of unmetabolized [N-methyl-
11C]mir-
tazapine remained in the bloodstream throughout the
scan, with 30% to 60% of the radioactivity in the blood-
stream arising from unmetabolized [N-methyl-
11C]mir-
tazapine at a 25-min postinjection and 20% to 40% of
[
11C]-derived radioactivity stemming from an unmetabo-
lized parent compound at the end of the 60-min scan.
The range of values of [N-methyl-
11C]mirtazapine in the
bloodstream tended to increase with time, perhaps due
partly to uncertainties in detecting the compound as
radioactivity gradually declined.
Table 1 shows the distribution volume of [N-methyl-
11C]mirtazapine estimated by methods A, B, and C. Sta-
tistical analysis of the data indicated that the weighting
procedure failed to significantly affect the estimates of
distribution volumes (Mann-Whitney U two-tailed test,
p = 0.85), so the data obtained with and without weight-
ing were pooled and used subsequently. Since the two-
tissue compartment model sometimes produced nega-
tive values for kinetic parameters, additional fits were
made in order to always obtain a positive estimate of
the distribution volume of [N-methyl-
11C]mirtazapine.
Despite that procedure, the statistical analysis confirmed
that the estimates of distribution volumes provided by
the three methods differed significantly (c
2 = 24.4, df =
2, p = 0.001), and the table shows that the two-tissue
compartmental model produced higher and more vari-
able values than those provided by methods A and C.
Table 2 shows estimates of the binding potentials of
[N-methyl-
11C]mirtazapine obtained by the six methods.
The weighting procedure failed to significantly affect the
estimates of binding potentials (Mann-Whitney U two-
tailed test, p =0 . 6 8 ) ,s ot h ed a t ao b t a i n e dw i t ha n d
without weighting were pooled for each method and
used for subsequent statistical tests. The statistical ana-
lysis confirmed that the estimates of binding potentials
of [N-methyl-
11C]mirtazapine provided by the six meth-
ods differed significantly (c
2 = 64.4, df = 5, p < 0.001),
and it is evident from the table that the values obtained
by the two-tissue compartment model differed markedly
from those provided by the other methods.
Table 3 compares the values for the binding potentials
of [N-methyl-
11C]mirtazapine obtained by pairs of meth-
ods. The statistical analysis showed that the values
obtained by the two-tissue compartment model (i.e.,
method B) were significantly higher than those obtained
by each of the other methods. Moreover, the graphical
reference tissue model (i.e., method D) produced values
of the binding potential that were significantly lower
than those obtained by the graphical plasma input
model, the reference tissue model, and the simplified
reference tissue model (p values < 0.05), while the bind-
ing potential values obtained by the graphical plasma
input method, the reference tissue model, and the sim-
plified reference tissue model did not differ significantly.
Table 4 presents correlations between the values for
the binding potential of [N-methyl-
11C]mirtazapine
obtained by pairs of methods. The values obtained by
the single-tissue compartment model (i.e., method A)
correlated significantly with those obtained by the gra-
phical plasma input model and the graphical reference
tissue model (i.e., methods C and D, respectively). In
addition, the values obtained by the graphical plasma
input model correlated significantly with those obtained
by the graphical reference tissue model and the simpli-
fied reference tissue model. A reliable correlation also
occurred between the reference tissue model (method E)
and the simplified reference tissue model (method F) for
the binding potential values.
Table 5 compares Akaike values for fits of the data by
methods A, B, E, and F, the methods that use all data
points for estimating the binding potential. The weight-
ing procedure failed to affect the Akaike values signifi-
cantly although there was a tendency for weighing to
reduce the Akaike scores (Mann-Whitney U two-tailed
test p = 0.08). The data obtained with and without
weighting were pooled for subsequent statistical tests.
The Akaike values obtained by methods A, B, E, and F
differed significantly (mean ± s.e.m. 77 ± 3, 41 ± 6, 18 ±
5, and 23 ± 5, respectively; Kruskal-Wallis H test, p <
0.001). Subsequent statistical analysis showed that the
Akaike values obtained by method A, the single-tissue
compartment model, were significantly greater than
those obtained by the other three methods (p values <
0.05). On the other hand, the Akaike values provided by
the reference tissue model (method E) were significantly
smaller than the scores obtained by the two-tissue com-
partment model (method B) (p < 0.05).
Discussion
Central actions of psychotropic drugs continue to be of
interest in PET brain imaging [22-24]. Our work shows
that mirtazapine, an effective antidepressant drug, has
favorable properties for PET brain imaging when the
compound is radiolabeled with
11Ci nt h eN-methyl
position [10,25,26]. As far as we know, [N-methyl-
11C]
mirtazapine is the only radioligand of a popular antide-
pressant drug that is suitable for PET imaging of the
brain in humans. We realize, of course, that mirtazapine
affects multiple receptor systems, including alpha-adre-
nergic, histamine type 1, and serotonin type 2 [5,27,28]
receptors. Some may view the lack of receptor specificity
of [N-methyl-
11C]mirtazapine as a disadvantage for PET
neuroimaging, whereas we view the radioligand as a
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Figure 2 Time-radioactivity curves for [N-methyl-
11C]mirtazapine in the bloodstream and the brain.( A)P e r c e n t a g eo f[
11C]-derived
radioactivity corresponding to the unmetabolized [N-methyl-
11C]mirtazapine in the bloodstream of each subject after intravenous injection. The
five symbols correspond to the five subjects. (B) Decay-corrected time-radioactivity curves for [
11C]mirtazapine in the plasma after intravenous
bolus injection in one subject. (C) Decay-corrected time-activity curves for [
11C]mirtazapine in brain regions in one subject.
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disorders in the living human brain.
Several methods are currently in use for studying the
pharmacokinetics of PET radioligands [29,30]. Of parti-
cular interest for the present report are methods requir-
ing no arterial cannulation.
We have, therefore, compared kinetic models, with
and without the requirement of arterial cannulation, for
estimating the distribution volume and binding potential
of [N-methyl-
11C]mirtazapine in the living human brain.
In a previous study, we used method A, the single-tissue
compartment model with arterial cannulation, for asses-
sing the pharmacokinetics of the radiotracer. That
method has few parameters and typically provides stable
fits with reproducible estimates of parameters. However,
some volunteers experienced pain at the site of cannula-
tion. In addition, the relatively high Akaike scores found
for that method indicate that the single-tissue compart-
ment model may oversimplify the dynamics of [N-
methyl-11C]mirtazapine data, perhaps resulting in
biased estimates of parameters. The values for the bind-
ing potential of [N-methyl-
11C]mirtazapine obtained by
method A were, for instance, markedly lower than those
obtained by the other nonlinear methods assessed in the
present study (i.e., methods B, E, and F). Moreover, the
estimates of binding potentials were poorly correlated to
those of the other nonlinear methods.
Table 1 Distribution volume of [N-methyl-
11C]mirtazapine
estimated using three methods
Method Region Subject
12 345
A 1 6.3 7.9 5.4 6.6 6.5
2 9.0 11.2 9.6 10.2 10.2
3 11.9 14.1 10.7 13.3 11.7
4 8.6 10.6 10.5 9.8 10.3
5 8.8 10.8 9.1 10.1 9.4
B 1 297.9 7.9 5.4 8.6 7.2
2 25.2 11.6 9.7 33.4 18.3
3 187.1 14.1 10.9 39.1 14.0
4 26.5 34.3 11.0 31.6 17.3
5 19.2 10.8 9.2 169.5 39.9
C 1 7.7 7.7 5.2 9.0 6.9
2 11.9 11.4 9.6 14.2 11.8
3 17.8 15.0 10.6 25.9 13.4
4 13.8 11.7 11.4 18.5 13.1
5 10.8 10.4 8.9 13.7 10.2
Method A is the single-tissue compartment model with uncorrected and
metabolite-corrected arterial plasma input functions. Method B is the two-
tissue compartment model with uncorrected and metabolite-corrected arterial
plasma input functions. Method C is the graphical plasma input model with
metabolite-corrected arterial plasma input function. Region 1 is the
cerebellum, region 2 is the striatum, region 3 is the hippocampus, region 4 is
the frontal lobe, and region 5 is the thalamus.
Table 2 Binding potential of [N-methyl-
11C]mirtazapine
estimated using six methods
Method Region Subject
12345
A 2 0.44 0.41 0.78 0.54 0.56
3 0.99 0.78 0.99 1.00 0.80
4 0.36 0.34 0.94 0.47 0.57
5 0.40 0.36 0.69 0.51 0.44
B 2 2.94 0.35 34.3 3.58 1.34
3 26.1 5.71 23.4 4.53 0.98
4 4.90 3.72 11.3 5.22 1.90
5 1.74 0.25 10.0 21.6 3.77
C 2 0.55 0.47 0.83 0.58 0.70
3 1.32 0.94 1.04 1.89 0.93
4 0.81 0.51 1.17 1.06 0.88
5 0.41 0.34 0.70 0.53 0.46
D 2 0.42 0.35 0.77 0.48 0.57
3 0.78 0.61 0.91 0.88 0.72
4 0.38 0.27 0.98 0.43 0.59
5 0.38 0.29 0.69 0.45 0.43
E 2 0.52 1.16 0.91 0.61 0.66
3 1.28 1.53 1.07 1.15 0.98
4 1.01 2.18 1.79 0.79 1.62
5 0.38 0.32 0.72 0.45 0.45
F 2 0.51 0.85 0.99 0.56 0.97
3 1.10 1.06 1.32 1.14 1.05
4 1.58 2.67 3.11 1.08 2.85
5 0.39 0.32 0.82 0.47 0.45
Method A is the single-tissue compartment model with uncorrected and
metabolite-corrected arterial plasma input functions. Method B is the two-
tissue compartment model with uncorrected and metabolite-corrected arterial
plasma input functions. Method C is the graphical plasma input model with
metabolite-corrected arterial plasma input function. Method D is the graphical
reference tissue model with a cerebellum time-activity curve. Method E is the
reference tissue model with a cerebellum time-activity curve. Method F is the
simplified reference tissue model with a cerebellum time-activity curve.
Region 2 is the striatum, region 3 is the hippocampus, region 4 the is frontal
lobe, and region 5 is the thalamus.
Table 3 Comparisons of binding potentials of [N-methyl-
11C]mirtazapine estimated by six methods
Method
a BCDEF
A 5.3* 2.5 0.9 3.5* 3.9*
B 4.7* 5.5* 4.1* 3.7*
C 3.2* 1.4 2.0
D 4.0* 4.4*
E 0.6
aSee the legend of Table 2 for a description of the methods. The
nonparametric statistical comparison (z-scores) in the table denotes the
degree of difference between the binding potential values provided by the
methods; *the binding potentials obtained by the two methods differed
significantly (two-tailed tests, Bonferroni correction for multiple comparisons,
p ≤ 0.0016).
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vided better fits than method A of the PET data for [N-
methyl-
11C]mirtazapine, judging from Akaike scores.
The fits of method B were, however, highly sensitive to
the initial guess and often had to be redone in order to
obtain non-negative estimates of parameters. Further-
more, the microparameters k3 and k4 were poorly deter-
mined by method B, which lead to variable estimates of
VT and BPND that differed markedly from the values
obtained with other methods. This lack of robustness of
method B limits its use for modeling of the [N-methyl-
11C]mirtazapine data. It is noteworthy, however, that
method B described the data very well, judging from
Akaike values, which suggests that at least two-tissue
compartments are kinetically distinguishable for [N-
methyl-
11C]mirtazapine, namely free and specifically-
bound ligand, assuming that the free and nonspecifically
bound compartments reach equilibrium rapidly. One
could speculate that a slower, nonspecific component of
binding might also be present using a third compart-
ment for the radioligand, but we did not examine that
model in the present study, in part due to uncertainties
that can arise from an excessive number of parameters.
The graphical linear models, methods C and D, pro-
vide estimates of macroparameters that are independent
of the underlying compartment scheme. We found that
the values of binding potentials provided by methods C
and D were reliably correlated. In addition, BPND
estimates using method C were similar to those
obtained by the nonlinear reference region methods E
and F. In contrast, method D provided BPND values that
were markedly lower than those obtained with methods
C, E, and F, and the estimates of binding potential pro-
vided by method D were not reliably correlated to those
obtained using methods E and F. Thus, the estimates of
BPND provided by method C corresponded better than
those of method D to BPND values of [N-methyl-
11C]
mirtazapine obtained by the nonlinear methods. How-
ever, several factors affect BPND values obtained by the
standard implementations of methods C and D used in
the present study [14,15,31]. Firstly, exclusion of vascu-
lar volume in method C causes distribution volumes to
be overestimated and binding potentials to be underesti-
mated, although the bias may be small [14]. In accor-
dance with that, we found in supplementary studies that
the effect was of minor importance for [N-methyl-
11C]
mirtazapine, being less than 3%. Secondly, exclusion of
the k2-correction term for method D can cause underes-
timation of the VT ratio [15], and noisy data can cause
slopes to be underestimated by both methods [31].
Thirdly, because methods C and D involve fitting of the
slope of the linear part of the Logan plot, curvature of
the plot throughout the duration of scanning impairs
the estimation of the binding potential (see Figure 3).
Since the binding of [N-methyl-
11C]mirtazapine may be
relatively slow in some brain regions, methods C and D
may have underestimated the distribution volumes and
binding potentials in such regions under the conditions
of the present study. Perhaps lengthening the duration
of the scanning interval could minimize this potential
source-of-error so that methods C and D could be used
routinely for estimating the binding potential of [N-
methyl-
11C]mirtazapine.
The reference tissue model (method E) and the sim-
plified reference tissue model (method F) are nonlinear
procedures that rely on the entire data set. The BPND
values obtained by the two methods were reliably corre-
lated and did not differ significantly. The present find-
ings show that methods E and F described the data
better than methods A and B, judging from Akaike
scores. This could be partly due to the variance inherent
in the analysis over time of rapidly decaying radionu-
clides in the bloodstream.
Methods E and F use the cerebellum as a tissue-reference
region for the indirect input function of [N-methyl-
11C]
mirtazapine, based on previous findings [9]. The present
findings show, however, that [N-methyl-
11C]mirtazapine in
the cerebellum may be described by two compartments
(see Figure 4): a free compartment and a small compart-
ment of nonspecific binding. If two compartments are pre-
sent for [N-methyl-
11C]mirtazapine in the cerebellum, then
methods E and F may underestimate the binding potential
Table 4 Correlations between binding potentials of [N-
methyl-
11C]mirtazapine obtained by six methods
Method
a BCDEF
A 0.52 0.83* 0.98* 0.39 0.42
B 0.56 0.60 0.27 0.35
C 0.83* 0.60 0.72*
D 0.38 0.45
E 0.90*
aSee the legend of Table 2 for a description of the methods. The
nonparametric Rho scores in the table denote the correlation between the
binding potential values provided by the methods; *statistically significant
correlations (two-tailed tests, Bonferroni correction for multiple comparisons, p
≤ 0.0016).
Table 5 Comparisons of Akaike values for nonlinear fits
of [N-methyl-
11C]mirtazapine-PET data
Method
a BEF
A 4.7* 6.9* 7.1*
B 2.9* 2.5
E 0.5
aSee the legend of Table 2 for a description of the methods. The
nonparametric statistical comparison (z-scores) in the table reflects the degree
of difference between the binding potential values provided by the methods
being compared. *Akaike values obtained by the two methods differed
significantly (two-tailed tests, Bonferroni correction for multiple comparisons,
p ≤ 0.0042). A nonsignificant z-score indicates that the Akaike values provided
by the two methods did not differ reliably.
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Figure 3 Decay-corrected time-radioactivity curves for [N-methyl-
11C]mirtazapine in the thalamus and hippocampus fitted by method
D. Method D is the graphical reference tissue model. Note in the Logan representation that the data of the thalamus become linear within 60
min, whereas the data of the hippocampus exhibit a curvature for a longer time.
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Figure 4 Decay-corrected time-radioactivity curve for [N-methyl-
11C]mirtazapine in the cerebellum of a single subject. Note that the
data are fitted better by method B (two-tissue compartment model; Akaike score, 31.8) than by method A (single-tissue compartment model;
Akaike score, 46.1).
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Page 8 of 10of the radioligand [16]. Unlike method E, method F
requires that rates of exchange between the free, possibly
nonspecific, and specific compartments are so fast that
they are kinetically indistinguishable [17]. That assumption
may be incorrect for [N-methyl-
11C]mirtazapine because
multiple components may have been identified by methods
A and B (see Figure 3), making method F less appropriate
than method E for estimating regional binding potentials
in the living human brain.
In this paper, we have compared estimates of kinetic
parameters using [N-methyl-
11C ] m i r t a z a p i n ed a t ai na
homogenous group of volunteers. Six models were evalu-
ated based on their robustness and by statistical compari-
sons of their parameter estimates and ability to describe
data. In a future work, a comparison study between dif-
ferent groups of subjects could be used to further validate
the parameter estimates and the model selection.
Conclusions
Taken together, the present findings indicate that the
reference tissue model is appropriate for use in PET
imaging for obtaining estimates of pharmacokinetic
parameters, such as the binding potentials of [N-methyl-
11C]mirtazapine in regions of the living human brain.
Since that method does not depend on metabolite-cor-
rected plasma input functions, we conclude that the
binding potentials of [N-methyl-
11C]mirtazapine in
brain regions can be estimated without arterial cannula-
tion by PET in humans.
A shortcoming of the present study concerns complica-
tions that can arise in the kinetic analysis of compounds
studied as racemates [32]. However, the enantiomers of
[N-methyl-
11C]mirtazapine failed to show marked differ-
ences in the binding kinetics in laboratory animals and
healthy humans [26,33]. We conclude, therefore, that
analysis of PET data using the reference tissue model for
racemic [N-methyl-
11C]mirtazapine can provide insight
into antidepressant actions that cannot otherwise be stu-
died in the living human brain.
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